TABLE 3.

Sensitivity Analyses

Bladder Antispasmodic	Primary Analysis Main Findings RR (95% CI)	Sensitivity Analysesa
		1. Lost to Follow-up Treated as Discontinued RR (95% CI)	2. Alternative Persistence Definition RR (95% CI)	3. Alternative Outcome, PDC ≥ 80% RR (95%CI)	4. Persistence > 90 Days OR (95% CI)b
Tolterodine, long acting	1.0 [Reference]	1.0 [Reference]	1.0 [Reference]	1.0 [Reference]	1.0 [Reference]
Tolterodine, short acting	0.90 (0.85-0.94)	0.90 (0.86-0.95)	0.89 (0.84-0.94)	0.83 (0.78-0.87)	0.89 (0.82-0.97)
Trospium, long acting	0.97 (0.85-1.12)	0.98 (0.85-1.13)	1.01 (0.87-1.18)	0.91 (0.78-1.06)	0.98 (0.77-1.25)
Trospium, short acting	0.95 (0.89-1.02)	0.94 (0.88-1.01)	0.96 (0.89-1.04)	0.87 (0.81-0.94)	0.91 (0.81-1.02)
Solifenacin	1.08 (1.03-1.13)	1.08 (1.03-1.14)	1.09 (1.03-1.15)	1.06 (1.01-1.12)	1.17 (1.07-1.29)
Darifenacin	1.04 (0.95-1.13)	1.02 (0.93-1.12)	1.07 (0.97-1.17)	1.07 (0.98-1.17)	1.10 (0.93-1.31)
Fesoterodine	1.25 (1.09-1.43)	1.27 (1.10-1.47)	1.31 (1.12-1.52)	1.23 (1.06-1.43)	1.54 (1.14-2.09)

^aAll log-binomial regression models included random intercepts for VA medical center and year and were adjusted for all demographic, clinical conditions, and urological management variables included in the primary analysis (see Table 2).

^bThe log-binomial model did not converge. We therefore presented findings for sensitivity analysis #4 in terms of ORs based on logistic regression using the same random intercepts and adjustment variables. While the magnitude of the OR and RR estimates are not directly comparable, the treatment effects reaching statistical significance are consistent with the primary analysis and other sensitivity analyses.

CI = confidence interval, OR = odds ratio; PDC = proportion of days covered, RR = relative risk.